Previous 10 | Next 10 |
2023-05-08 10:03:22 ET Gainers: Immuron ( IMRN ) +49% . ANI Pharmaceuticals ( ANIP ) +17% . MiNK Therapeutics ( INKT ) +13% . Evaxion Biotech ( EVAX ) +8% . Predictive Oncology ( POAI ) +8% . Losers: Catalent ( CTLT ) ...
2023-05-08 07:03:04 ET Aclaris Therapeutics press release ( NASDAQ: ACRS ): Q1 GAAP EPS of -$0.42 beats by $0.02 . Revenue of $2.53M (+74.5% Y/Y) beats by $0.78M . The increase was driven by higher licensing revenue primarily from royalties earned on out-licens...
- Management to Host Conference Call at 8:00 AM ET Today – WAYNE, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announ...
2023-05-05 12:16:05 ET Aclaris Therapeutics ( NASDAQ: ACRS ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$0.44 (-41.9% Y/Y) and the consensus Revenue Estimate is $1.75M (+20.7% Y/Y). Over the last ...
2023-05-05 11:40:34 ET Major earning expected before the bell on Monday include: BioNTech ( BNTX ) DISH Network ( DISH ) KKR & Co. ( KKR ) Tyson Foods ( TSN ) Viatris ( VTRS ) For further details see: Notable earnings before Monday's open
WAYNE, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2023 on Monday, M...
2023-04-24 14:37:47 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In a high-interest-rate environment, cash is king. All biotech companies will need to continue spending to finance their R&D. But debt-fueled spending is becoming expensive. And selling sto...
2023-04-12 17:16:26 ET Gainers: Dragonfly Energy Holdings ( DFLI ) +5% . C4 Therapeutics ( CCCC ) +5% . Sana Biotechnology ( SANA ) +4% . SunPower Corporation ( SPWR ) +3% . Cogent Biosciences ( COGT ) +3% . Losers: ...
WAYNE, Pa., March 27, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fire...
2023-03-09 07:30:00 ET Summary Aclaris Therapeutics reported disappointing marks for zunsemetinib’s “ATI-450” Phase IIa trial for moderate to severe hidradenitis suppurativa. The share price has been nearly chopped in half. The trial missed the primary and sec...
News, Short Squeeze, Breakout and More Instantly...
Aclaris Therapeutics Inc. Company Name:
ACRS Stock Symbol:
NASDAQ Market:
Aclaris Therapeutics Inc. Website:
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities - - $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company ...
WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, Interim President & CEO of Aclaris, will part...
- Progressing ATI-2138 into Atopic Dermatitis - - Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidat...